Alivira adquire 70% da Interchange Brasil por US $ 3,6 milhões

A empresa farmacêutica indiana SeQuent Scientific  comunica que sua subsidiária Alivira Animal Health Limited irá adquirir uma participação equivalente a 70 por cento da Interchange Indústria e Comércio de Produtos Veterinários SA, instalada e Campinas, SP, por US $ 3,6 milhões.

A Interchange atua há mais de 21 anos na terapia das doenças de Aves, Suínos e Bovinos, e em 2015, faturou U$ 5,8 milhões, com EBITDA de 4%.

==============
Alivira to acquire controlling interest in Interchange Brazil Forays into Brazil, the third largest veterinary market

Mumbai, April 15, 2016 SeQuent Scientific Limited today announced that its subsidiary Alivira Animal Health Limited (Alivira) has signed a definitive agreement to acquire 70% stake in Interchange Indústria e Comércio de Produtos Veterinários S.A. Brazil(“Interchange Brazil”)

The transaction is expected to close in the current quarter and subject to customary closing conditions and approval of the competent courts in Brazil. The acquisition will be made through a step down subsidiary in Brazil of Alivira Ireland, a wholly owned subsidiary of the Company.

Strategic Benefits

• Brazil is the third largest veterinary market in the World accounting for 7.5% of the global animal health business. Estimated at $1.2bn in 2015, Brazilian veterinary market is growing at 10.5% which is twice the average global veterinary growth.
• Brazil has the largest commercial bovine herd. It is number two in poultry market and has the fourth largest swine population in the world.
• Interchange, operating under the trade-name Evance is amongst the ‘Top 10’ Brazilian Companies operating in the veterinary health space with a focus on poultry and swine segments. The company was founded in 1995 and operates from a modern production plant, meeting the good manufacturing practices required by the Ministry of Agriculture in Brazil.
• The company has a portfolio of over 25 registered products consisting of antimicrobials, parasiticides, sanitizers and products for therapeutic support.
• Interchange’s current management team is led by Mr. Jose Nunes Filho, a person of eminence in the Brazilian market with over 40 years of experience in the animal health market.
• The Company registered sales of $5.8mn in 2015 with an EBITDA of 4%. As part of the transaction, Alivira will invest $3.6mn to acquire 70% stake in the company, of which $2.2mn would be fresh infusion into the company to accelerate growth. Leia mais em Sequent 15/04/2016